Navigation Links
Both Biosimilar and Reference Biologics Companies Must consider Various Product-Specific and Regional Strategies to Navigate a Dynamic and Uncertain Global Market
Date:4/8/2013

EXTON, Pa., April 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, with sales forecasted to exceed $16.8 billion by 2021, manufacturers competing in the biosimilars market must adopt clear and effective strategies early in product development to maximize potential commercial return. According to Biosimilars Advisory Service: Corporate Strategies, after identifying an optimal biologic target and determining partnerships, biosimilar sponsors need to balance clinical development burdens with sales and marketing strategies and the option of pursuing interchangeability status in the United States in order to compete successfully.

The 2013 Biosimilars Advisory Service report finds that, despite a continued increase of branded biologics sales through 2014, the entrance of commercially relevant, lower-cost biosimilars and resultant brand price cuts will cause the overall biologics market to decrease over the second half of the forecast period across the seven major pharmaceutical markets.

"Innovator companies stand to lose considerable revenue from their key biologic drugs as a result of biosimilar erosion, especially those that rely heavily on biologic sales with near-term patent expiries," said Andrew Merron , Ph.D., Senior Director, Biosimilars Research at Decision Resources Group. "It's imperative for these companies and biosimilars manufacturers to adopt product-based and regional strategies individualized by their respective challenges and opportunities."

Based on analysis of surveys from over 600 key industry stakeholders and extensive secondary market research, report findings reveal that branded biologics companies should implement unique, product-specific strategies focusing on the development of biobetters, a reliable legal defense, alternative pricing tactics and potential counter-detailing messages to combat biosimilar competition.

The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.Bio-Trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:BioTrends Research Group Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604

781-993-2563athrower@dresourcesgroup.com

emarshall@dresourcesgroup.com 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
2. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
3. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
4. ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming; Urges Distinct Naming Requirement
5. Reliance Pharmaceuticals: Biosimilars Company Analysis
6. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
7. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
8. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
9. Musculoskeletal Network Launches Special Coverage of FDA Biosimilars Policy
10. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
11. Global Biosimilars: A return to optimism?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology:
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... and other leading institutions in announcing the launch of the Leadership Circle ... way animals are raised for food. , Founding members of the Leadership Circle ...
Breaking Medicine News(10 mins):